Thermo Fisher Acquires Affinity BioReagents | GenomeWeb
NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it has acquired privately held antibody maker Affinity BioReagents for an undisclosed amount.
 
Golden, Colo.-based Affinity makes monoclonal and polyclonal antibodies, peptides, proteins, and other reagents. The firm, which offers more than 35,000 reagents, also provides recombinant proteins and custom antibody-production services, said Thermo Fisher.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.